# Former FDA Commissioner Stephen Hahn Joins BreakBio as Advisor to Guide Cancer Drug Strategy

> BreakBio, a Miami biotech designing personalized peptide immunotherapies, named former FDA Commissioner Dr. Stephen Hahn.

- Published: 2026-10-26T10:37:09+00:00
- Section: Leadership
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-26/breakbio-stephen-hahn-advisor
- Source: [EIN Presswire](https://www.einnews.com/pr_news/951874106/former-fda-head-dr-stephen-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advisor)

## Key takeaways

- Dr. Stephen Hahn, the FDA's 24th Commissioner, joined BreakBio as an advisor on clinical development, regulatory strategy, oncology, platform development and corporate strategy.
- BreakBio CEO and Co-Founder Roy de Souza said Hahn's experience with new therapeutic platforms is valuable as the company advances its personalized drugs.
- BreakBio is developing personalized peptide-based immunotherapies that target both mutated and non-mutated cancer-associated proteins.

Dr. Stephen Hahn, who led the FDA as its 24th Commissioner, joined [BreakBio](https://akta.pro/company-profiles/0009v2s/breakbio) as an advisor, the company said on October 26, 2026. Hahn will advise the Miami-based personalized cancer drug developer on clinical development, regulatory strategy, oncology, platform development and corporate strategy, according to [EIN Presswire](https://www.einnews.com/pr_news/951874106/former-fda-head-dr-stephen-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advisor).

## Hahn's Role at BreakBio

Hahn oversaw reviews of COVID-19 therapeutics and the Emergency Use Authorizations for the Moderna and Pfizer-BioNTech vaccines during his time at the FDA. Before that, he chaired Radiation Oncology at the University of Pennsylvania, then served at MD Anderson as Division Head and Chair of Radiation Oncology, Deputy President and Chief Operating Officer, and Chief Medical Executive. He later joined Flagship Pioneering as Chief Medical Officer of its Preemptive Medicine initiative, became a Flagship CEO-Partner and CEO of Harbinger Health, and is now CEO of Nucleus RadioPharma.

"Steve has had a front-row seat to fundamentally new therapeutic platforms," said Roy de Souza, BreakBio CEO and Co-Founder. "That combination of experience is extraordinarily valuable as BreakBio works to advance its best-in-class personalized drugs."

Hahn said recent clinical trial results mark an inflection point, with personalized drugs having demonstrated meaningful efficacy while also being practical to manufacture for individual patients. "I believe we are entering a new era of medicine in which therapies designed for each patient become an important new class of pharmaceuticals—and BreakBio has the potential to play a significant role in that transformation," he said.

BreakBio is developing personalized peptide-based immunotherapies designed using the unique molecular characteristics of each patient's tumor. Unlike approaches focused primarily on mutation-derived neoantigens, BreakBio targets both mutated and non-mutated cancer-associated proteins, which the company says could expand personalized immunotherapy to a broader range of solid tumors and patients.

## BreakBio's Clinical and Platform Record

According to akta.pro [company records](https://akta.pro/company-data), BreakBio initiated enrollment for a Phase 1/2 clinical trial of its personalized peptide immunotherapy in Triple Negative Breast Cancer, with a 45-day biopsy-to-treatment manufacturing window. The same records show an FDA Investigational New Drug application approved and an indication-agnostic platform designed to treat any solid cancer by targeting unique mutations of each individual patient. BreakBio was founded in 2017 following the founder's personal experience developing a personalized cancer vaccine for his wife in Germany, the records state.

## Hahn's Advisory Scope

Hahn will advise BreakBio on clinical development, regulatory strategy, oncology, platform development and corporate strategy, the company said. BreakBio describes itself as a private company developing personalized drugs for cancer and other non-transmissible diseases that differ in each patient.

## Companies in this story

- [BreakBio company profile](https://akta.pro/company-profiles/0009v2s/breakbio) · website: https://breakbio.com

---
News for Agent · https://newsforagent.com/llms.txt